Skip to ContentSkip to Navigation
About us Latest news News News articles

Towards a cross-protective influenza vaccine

12 December 2012

PhD ceremony: Ms. N. van Braeckel Budimir, 14.30 uur, Academiegebouw, Broerstraat 5, Groningen

Dissertation: Towards a cross-protective influenza vaccine

Promotor(s): prof. J.C. Wilschut, prof. A.L.W. Huckriede

Faculty: Medical Sciences

Although vaccination is the cornerstone of influenza prevention, and current inactivated influenza vaccines are safe, there is an increasing demand for further improvement of these vaccines. Indeed, influenza vaccine efficacy is suboptimal in a number of important target groups for vaccination, particularly the elderly and young children.

Current influenza vaccines induce a narrow and strain-specific immune response and fail to protect against different antigenic variants and subtypes. Therefore, development of vaccines capable of inducing a broadly protective immune response is required. One possible approach, addressed in this thesis, is to aim for induction of cross-protective Cytotoxic T-Lymphocytes (CTLs) specific for antigenic determinants that are conserved among different influenza variants and subtypes. This study demonstrates that Whole Inactivated Influenza (WIV) vaccine has the capacity to induce heterosubtypic cross-protection, mainly mediated by CTLs. CTL-inducing capacity of WIV is highly influenced by the virus inactivation method, as some treatments, such as Formalin-inactivation, severely compromise membrane fusion activity of WIV, required for successful delivery of antigen into the cytosol of antigen-presenting cell. Furthermore, we showed that heterosubtypic cross-protection induced by WIV vaccination critically depends on activation of Toll-like receptor 7 (TLR7) in dendritic cells, which is required for successful antigen cross-presentation. Finally, our results show that parenteral routes of WIV administration are superior in comparison to mucosal vaccination in terms of induction of cross-protective CTL responses. Taken together, our findings appear to support reconsideration of WIV as a “novel” vaccine formulation for induction of broadly protective immunity against influenza.

Last modified:13 March 2020 01.02 a.m.
Share this Facebook LinkedIn
View this page in: Nederlands

More news

  • 24 March 2025

    UG 28th in World's Most International Universities 2025 rankings

    The University of Groningen has been ranked 28th in the World's Most International Universities 2025 by Times Higher Education. With this, the UG leaves behind institutions such as MIT and Harvard. The 28th place marks an increase of five places: in...

  • 05 March 2025

    Women in Science

    The UG celebrates International Women’s Day with a special photo series: Women in Science.

  • 28 February 2025

    Vici grants for two UG/UMCG scientists

    The Dutch Research Council (NWO) has awarded Vici grants, worth up to €1.5 million each, to Merel Keijzer and Charalampos Tsoumpas This will enable the researchers to develop an innovative line of research and set up their own research group for...